Document Detail


Factors associated with success of the extreme drug resistance assay in primary breast cancer specimens.
MedLine Citation:
PMID:  11881914     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The extreme drug resistance (EDR) assay has not been widely studied in the setting of non-metastatic breast cancer. We evaluated the feasibility of performing the assay in 144 primary breast tumor specimens from two institutions by determining the rate of successful tumor culture for assays, number of drugs evaluated per assay, and time from tumor biopsy to receipt of results. We also sought to determine factors that are associated with assay success. An exploratory analysis was performed to detect possible associations between estrogen receptor (ER), progesterone receptor (PR) and HER2/NEU over-expression and extreme drug resistance demonstrated by the assay for specific chemotherapeutic agents. Of 144 tumor specimens submitted, tumor was successfully cultured for assay in 101(70%) of cases. A median of five drugs was evaluated per assay (range 2-9). Results were obtained in a median of 8 days (range 2-29). Young age, high tumor grade, PR negativity, and higher tumor submission weight were predictive for a successful assay. EDR was observed in 7-15% of tumors to doxorubicin, cyclophosphamide, 5-fluorouracil (5FU) and mitoxantrone, but EDR to paclitaxel was observed in 35%. Extreme drug resistance to 5-FU was associated with negative ER and PR status. There was a trend toward association between EDR to paclitaxel and HER2/NEU over-expression. The EDR assay may be successfully performed in the majority of tumors, and assay results are available in a timely fashion such that adjuvant treatment drug selection could be guided by results. These results may be helpful for designing possible future trials that evaluate the assay's role in adjuvant chemotherapy selection.
Authors:
Robert J Ellis; Carol J Fabian; Bruce F Kimler; Ossama Tawfik; Matthew S Mayo; Carlos Rubin Decelis; William R Jewell; Carol Connor; Carol Modrell; Mark Praeger; Marilee McGinness; Rita Mehta; John P Fruehauf
Related Documents :
21533524 - Characterization of bevacizumab dose response relationship in u87 brain tumors using ma...
23929794 - Maelstrom promotes hepatocellular carcinoma metastasis by inducing epithelial-mesenchym...
24566894 - Tumor cell plasticity: the challenge to catch a moving target.
21632104 - Magnetically-enabled and mr-monitored selective brain tumor protein delivery in rats vi...
2785214 - Macrophage activation by the polysaccharide arabinogalactan isolated from plant cell cu...
22148054 - Primary granulocytic sarcoma of the face.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Breast cancer research and treatment     Volume:  71     ISSN:  0167-6806     ISO Abbreviation:  Breast Cancer Res. Treat.     Publication Date:  2002 Jan 
Date Detail:
Created Date:  2002-03-07     Completed Date:  2002-09-04     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8111104     Medline TA:  Breast Cancer Res Treat     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  95-102     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, University of Kansas Medical Center, Kansas City 66160, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Age Factors
Antineoplastic Agents / toxicity*
Breast Neoplasms / classification,  pathology*
Cell Survival / drug effects
Cohort Studies
Drug Resistance, Multiple*
Drug Resistance, Neoplasm*
Female
Humans
Tumor Cells, Cultured
Chemical
Reg. No./Substance:
0/Antineoplastic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-...
Next Document:  Speech perception and spoken word recognition: past and present.